


Amendments to the Specification:

Please replace the paragraph starting on page 25, line 19 and ending on page 26, line 4 with the following:

A particularly preferred tetrapeptide unit: D-C-B-A is:




SEQ ID NO: 1 core


which may be joined at its N- and C- termini to any of the X or Z groups set out above.

Please replace the paragraph starting on page 26, line 24 and ending on page 27, line 4 with the following:

Preferred hexapeptides




include:



SEQ ID NO: 2 core


and



SEQ ID NO: 3 core


Please replace the paragraph starting on page 29, line 13 and ending on page 30, line 5 with the following:

Particularly preferred molecules of this aspect of the invention are hexapeptides. For example, the following formulae show preferred hexapeptides of the second aspect of the invention:



SEQ ID NO: 4 core

and




SEQ ID NO: 5 core

where Z is as defined above for the first aspect, and is preferably an acyl group, for example an acetyl group and R₁ is a fluorinated hydrocarbon side chain having from 1 to 15, preferably 2 to 10, particularly 2 to 8 carbon atoms.

Please replace the paragraph starting on page 41, line 34 and ending on page 42, line 9 with the following:

Preferably, the compound of formula Y-NH-CHR₂-CO₂H for reaction with a compound of formula K, L, M or N will be in protected form. For instance, any carboxylic acid groups other than that at the C terminus may preferably be protected, for instance as esters, eg as tertiary butyl esters. Examples of two highly preferred protected pentapeptides suitable for use in synthesis of hexapeptides


of the present invention are set out below and labelled (P) and (Q)



(P)

SEQ ID NO: 6

(acetylated at its amino terminus)



(Q)

SEQ ID NO: 7


(acetylated at its amino terminus)

Please replace the paragraph on page 44, line 3 (starting with "Example") and ending with "1a" with the following:

EXAMPLE 1: Synthesis of compound 1a: SEQ ID NO: 5
(acetylated at its amino terminus)

Please replace the paragraph starting on page 44, line 16 (starting with "The protected" and ending on page 44, line 19 (ending with a structure) with the following:


The protected pentapeptide shown below (ac-tert-butyl-aspartate-tert-butyl-glutamate-methylthio-tert-butyl-glutamate-tert-butyl-glutamate) was employed in this example



SEQ ID NO: 6 (acetylated at its amino terminus)

Please replace the paragraph on page 45, line 29 (starting with "This example") and ending on page 46, line 1 (ending with a structure):

This example, and also examples 3, 4 and 5 below, employed the protected pentapeptide shown below (Ac-tert-butyl-aspart-tert-butyl-glu-diphenylala-tert-butyl glu-cyclohexyl-ala)



SEQ ID NO: 7 (acetylated at its amino terminus)

Please insert the following paragraph legend at the end of the Table 1, on page 82:

Compound "1a" refers to a SEQ ID NO: 5 (acetylated at its amino terminus). Compound "1n" refers a SEQ ID NO: 5 (acetylated at its amino terminus) and modified at its carboxyl end by replacing C(O)OH with C(O)H.